349-66-6

Basic information

• Product Name: 2-HydroxyMethyl-5-trifluoroMethyl-phenol
• Synonyms: 2-HydroxyMethyl-5-trifluoroMethyl-phenol
• CAS NO: 349-66-6
• Molecular Formula: C₈H₇F₃O₂
• Molecular Weight: 192.1351896
• EINECS: -0
• Mol File: 349-66-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 66-66.5 °C(Solv: benzene (71-43-2))
• Boiling Point: 236.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.421±0.06 g/cm3(Predicted)
• PKA: 8.92±0.10(Predicted)
• CAS DataBase Reference: 2-HydroxyMethyl-5-trifluoroMethyl-phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-HydroxyMethyl-5-trifluoroMethyl-phenol(349-66-6)
• EPA Substance Registry System: 2-HydroxyMethyl-5-trifluoroMethyl-phenol(349-66-6)

Safety Data

• Hazardous Substances Data: 349-66-6(Hazardous Substances Data)

Usage

General Description

2-HydroxyMethyl-5-trifluoroMethyl-phenol is a chemical compound with the molecular formula C8H7F3O2. It is a phenolic compound that contains a hydroxyl group and a trifluoromethyl group, making it both hydrophilic and lipophilic, which gives it versatile solvent properties. This chemical is commonly used as an intermediate in the production of pharmaceuticals, agrochemicals, and other industrial chemicals. It possesses antioxidant and antifungal properties, making it a valuable ingredient in personal care products and cosmetics. Additionally, it has potential applications in the development of new materials and medical research. However, it is important to handle this chemical with caution and follow appropriate safety measures due to its potential for skin and eye irritation.

Upstream product

• 328-90-5 4-trifluoromethylsalicylic acid 

Downstream Products

• 58914-34-4 2-hydroxy-4-(trifluoromethyl)benzaldehyde 

Relevant articles and documents

Optical Control of CRAC Channels Using Photoswitchable Azopyrazoles

The Ca2+ release-activated Ca2+ (CRAC) channels control many Ca2+-modulated physiological processes in mammals. Hyperactivating CRAC channels are known to cause several human diseases, including Stormorken syndrome. Here, we show the design of azopyrazole-derived photoswitchable CRAC channel inhibitors (designated piCRACs), which enable optical inhibition of store-operated Ca2+ influx and downstream signaling. Moreover, piCRAC-1 has been applied in vivo to alleviate thrombocytopenia and hemorrhage in a zebrafish model of Stormorken syndrome in a light-dependent manner.

NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

MODULATORS OF DOPAMINE NEUROTRANSMISSION

The present invention relates to novel1-(4H-1,3-benzodioxin-2-yl)methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically asdopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.